Royal Bank Of Canada Liminal Bio Sciences Inc. Transaction History

Royal Bank Of Canada

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.32 - $0.5 $3,853 - $6,021	-12,042 Reduced 69.99%	5,164 $1,000
Q3 2022 Nov 14, 2022	SELL	$0.4 - $0.59 $690 - $1,018	-1,726 Reduced 9.12%	17,206 $7,000
Q2 2022 Aug 15, 2022	SELL	$0.44 - $0.97 $49 - $108	-112 Reduced 0.59%	18,932 $10,000
Q1 2022 May 16, 2022	BUY	$0.82 - $1.13 $9,827 - $13,543	11,985 Added 169.78%	19,044 $19,000
Q4 2021 Feb 14, 2022	BUY	$0.92 - $2.2 $763 - $1,826	830 Added 13.32%	7,059 $7,000
Q3 2021 Nov 15, 2021	SELL	$2.15 - $3.92 $836 - $1,524	-389 Reduced 5.88%	6,229 $15,000
Q2 2021 Aug 16, 2021	BUY	$3.75 - $5.17 $24,817 - $34,215	6,618 New	6,618 $26,000

234

Ticker LMNL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,042,600
Description
Liminal BioSciences Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel small molecule drug therapeutics for inflammatory, fibrotic, and metabolic diseases in Canada and the United Kingdom. The company's lead product candidate is fezagepras (PBI-4050), which has been completed Phase I clinical trial for the trea...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.